1140. Two-year Outcomes of Infected Total Hip Arthroplasty (THA) Treated With Debridement and Implant Retention
Session: Poster Abstract Session: Clinical Infectious Diseases: Bone and Joint, Skin and Soft Tissue
Friday, October 28, 2016
Room: Poster Hall
Background: Prosthetic joint infection (PJI) is a grave complication of total hip arthroplasty (THA). Two-stage exchange can be curative but is morbid and costly. Debridement, antibiotics, and implant retention (DAIR) is appropriate in some patients, but factors effecting success remain unclear. We studied a large cohort with infected THA treated with DAIR at our specialized orthopedic hospital, examining potential factors associated with 2-year implant retention.

Methods: A retrospective cohort of THA PJI treated with DAIR was identified by query of hospital coding records. Primary endpoint was defined as 2-year implant retention. Data from multiple sources included comorbidities, Musculoskeletal Infection Society (MSIS) criteria for PJI, duration of symptoms prior to surgery, time from index surgery, pathogen and sensitivities, surgical details, and treatment outcomes.

Results: 69 patients meeting MSIS criteria for THA PJI were identified. 62% of THA were retained at 2 years. Pathogens included methicillin-sensitive (22%) and methicillin-resistant Staphylococcus aureus (17%), coagulase-negative staphylococci (15%), and streptococci (22%); 6% of cases were culture-negative. Comorbidities included obesity (mean BMI 29.8), diabetes (15%), history of tobacco (39%), and rheumatologic disease (13%). No significant associations were noted between primary outcome and patient or implant age, BMI, comorbidities, or symptom duration at diagnosis. The 57% of patients who underwent polyethylene liner exchange (PLE) during debridement fared better than those who did not (77% vs. 43% success, p=0.004). Staphylococcal infections fared poorly, compared to non-staphylococcus (43% vs. 84% success, p<0.001); among staphylococcal PJI, rifampin use was not associated with success (28% vs. 58% success, p=0.065). In multivariable modeling, absence of staphylococcal infection (OR = 0.14, [95% CI 0.04-0.47], p=0.002) and PLE (OR = 4.7 [1.5-15], p=0.01) were associated with success.

Conclusion: We present 2-year outcomes on THA PJI treated with DAIR. The likelihood of implant retention is increased in non-staphylococcal infection and with polyethylene liner exchange. Our data may help guide evidence-based decision-making in THA PJI.

Andy Miller, MD1,2, Michael Henry, MD1,2, Devin Williams, MPH1, Scott Nodzo, MD3,4, Eileen Finerty, FNP CIC5, Allina Nocon, MPH6, Barry Brause, MD1,2 and Geoffrey Westrich, MD3,4,6, (1)Infectious Diseases, Hospital for Special Surgery, New York, NY, (2)Infectious Diseases, Weill Cornell Medicine, New York, NY, (3)Orthopedic Surgery, Hospital for Special Surgery, New York, NY, (4)Orthopedic Surgery, Weill Cornell Medicine, New York, NY, (5)Infection Control, Hospital for Special Surgery, New York, NY, (6)Complex Joint Reconstruction Center, Hospital for Special Surgery, New York, NY


A. Miller, None

M. Henry, None

D. Williams, None

S. Nodzo, None

E. Finerty, None

A. Nocon, None

B. Brause, None

G. Westrich, None

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.